BridgeBio Pharma, Inc. (BBIO) Friday shared positive results from the phase 3 study of acoramidis in adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM), conducted by Alexion, AstraZeneca Rare Disease in Japan.
Alexion, AstraZeneca Rare Disease, maintains an exclusive license with BridgeBio's affiliate, Eidos Therapeutics to develop and sell acoramidis in Japan.
In this study, no mortality was reported in patients treated with acoramidis for 30 months. The drug was well tolerated with no safety signals of potential clinical concern identified.
BridgeBio said that the results were consistent with its ATTRibute-CM Phase 3 trial, in which the primary endpoint was met.
Results from the trial support regulatory submission in Japan, the company said in a statement.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.